Wunderlich Securities Comments on Synergetics USA

Wunderlich Securities provided color on Synergetics USA

in a research report published today. Wunderlich Securities has a Buy rating and $8 price target on Synergetics. In the report, Wunderlich Securities states, "Combined with recent product introductions in the key Ophthalmology business, we believe SURG is in a strong position to exceed our full-year revenue and earnings expectations." Shares of Synergetics USA were trading at $6.15 at the time of posting, down 3.45% from Monday's market close.